Agmatine Modulation in Central Nervous System Disorders

Agmatine, a biogenic amine formed by the decarboxylation of L-arginine, has emerged as a multifunctional neuromodulator with relevance to a spectrum of central nervous system (CNS) disorders. It exerts diverse effects through interactions with imidazoline receptors, modulation of nitric oxide synthases and inhibition of N-methyl-D-aspartate (NMDA) receptors. Preclinical studies reveal that agmatine can attenuate excitotoxic injury, reduce inflammatory cytokine release, stabilise mitochondrial function and support blood–brain barrier integrity. Its capacity to reprogramme microglial metabolism, promote an anti-inflammatory glial phenotype and enhance antioxidant pathways underpins its potential in neurodegenerative conditions such as Alzheimer’s and Parkinson’s diseases, in acute insults including ischaemic stroke, and in chronic neuropathic pain. Oral administration achieves central accumulation, suggesting feasibility for translational development. Collectively, these findings highlight agmatine as a promising candidate for therapeutic modulation of neuroinflammation, oxidative stress and metabolic dysfunction across a range of CNS pathologies.

Research from Nature Portfolio

Recent studies have investigated the safety, tolerability and central neurochemical impact of daily oral agmatine administration in murine models. Sub-chronic dosing was well tolerated at high equivalent human doses, with no adverse behavioural or histopathological findings. Pharmacokinetic profiling demonstrated that exogenous agmatine readily crosses the blood–brain barrier, leading to sustained elevation of agmatine levels in multiple brain regions, including the hippocampus. Notably, accumulation was more pronounced in transgenic models of amyloid pathology. These results provide foundational evidence that therapeutic oral regimens can achieve effective central nervous system exposure without overt toxicity, thereby paving the way for further evaluation of agmatine in neurodegenerative and cognitive disorders.

Agmatine Modulation in Central Nervous System Disorders publication trend

The graph below shows the total number of articles in agmatine modulation in central nervous system disorders across all publications each year (not limited to Nature Index journals).

Technical terms

Agmatine: endogenous polyamine derived from L-arginine decarboxylation, modulating neurotransmission and cell signalling.

Microglia: resident immune cells of the CNS that orchestrate inflammatory and repair responses.

Blood–brain barrier (BBB): specialised endothelial interface regulating molecular exchange between blood and neural tissue.

PI3K/Akt/mTOR pathway: intracellular signalling cascade involved in cell survival, metabolism and inflammatory activation.

Nrf2: transcription factor activating antioxidant gene expression in response to oxidative stress.

NF-κB: transcription factor central to the regulation of pro-inflammatory gene expression.

References

1. Agmatine suppresses glycolysis via the PI3K/Akt/mTOR/HIF‐1α signaling pathway and improves mitochondrial function in microglia exposed to lipopolysaccharide. BioFactors (2025).
2. Safety and neurochemical profiles of acute and sub-chronic oral treatment with agmatine sulfate. Scientific Reports (2019).
3. Agmatine Mitigates Inflammation-Related Oxidative Stress in BV-2 Cells by Inducing a Pre-Adaptive Response. International Journal of Molecular Sciences (2022).
4. Effects of Agmatine on Blood-Brain Barrier Stabilization Assessed by Permeability MRI in a Rat Model of Transient Cerebral Ischemia. American Journal of Neuroradiology (2014).